What is SAGA Diagnostics?
SAGA Diagnostics AB is a pioneering company focused on personalized cancer diagnostics and disease monitoring. The firm specializes in advanced molecular genetic testing, utilizing both traditional tissue biopsies and innovative non-invasive "liquid biopsies" derived from samples such as blood. This approach allows for more precise and timely patient care, positioning SAGA Diagnostics at the forefront of precision oncology.
How much funding has SAGA Diagnostics raised?
SAGA Diagnostics has raised a total of $12.5M across 1 funding round:
Series A
$12.5M
Series A (2021): $12.5M with participation from Hadean Ventures and Segulah Medical Acceleration
Key Investors in SAGA Diagnostics
Hadean Ventures
Hadean Ventures is an investment firm that likely focuses on healthcare and life sciences, given the context of SAGA Diagnostics' work in cancer diagnostics.
Segulah Medical Acceleration
Segulah Medical Acceleration appears to be a venture capital entity specializing in accelerating medical technology companies, aligning with SAGA Diagnostics' mission.
What's next for SAGA Diagnostics?
The recent major strategic investment, following a Series A round, indicates SAGA Diagnostics is poised for significant scaling and further development of its diagnostic platforms. This capital infusion is expected to accelerate market penetration, enhance research and development capabilities, and potentially expand its service offerings to a broader patient and clinical base. The company's trajectory suggests a strong focus on solidifying its market position and driving innovation in cancer detection and management.
See full SAGA Diagnostics company page
